Recruiting
Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells
Registered drugNo placebo
Study Comparing Duvelisib with Gemcitabine or Bendamustine for Patients with Relapsed or Resistant T Cell Lymphoma Originating from T Follicular Helper Cells
Registered drugNo placebo
- Disease:Adult T-cell lymphoma/leukaemia refractory
- Substances:DuvelisibBendamustine Hydrochloride+1
Countries:
Belgium
Belgium- Participants:18–64 years · 65+ years
- Substances:Duvelisib
- Sponsor:Secura Bio Limited




